The US Food and Drug Administration (FDA) recently announced it is investigating Zantac (ranitidine hydrochloride), a heartburn and acid reflux treatment, after amounts of N-nitrosodimethylamine (NDMA) were found in the brand-name drug and in generic versions too. 

NDMA is a cancer-causing chemical and in July this year many blood pressure medications were recalled because they contained such a chemical. 

Zantac tablets have been found to contain 26,000 times the FDA-approved amount of NDMA that can be safely consumed daily. The FDA has recommended that people switch to another treatment option but has not issued a recall for Zantac.

Zantac belongs to the anti-ulcer, gastrointestinal agents class. Ranitidine is a histamine H2-receptor antagonist with antacid activity. It is a competitive and reversible inhibitor of the action of histamine at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. 

However, when ranitidine is ingested, it metabolises into NDMA. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Though Zantac has not been recalled, Novartis’s generics business (Sandoz) stated it has halted distribution of its generics versions in all markets. 

In addition, Zantac samples will still need to be tested and evaluated by the FDA, meaning this recent news will have a negative impact on both the branded and the generic versions.